Back to Results
First PageMeta Content
Biology / Haemophilia / Recombinant proteins / Peripheral membrane proteins / Blood products / Factor VIII / Factor VII / Bleeding / Cryoprecipitate / Blood / Anatomy / Coagulation system


Market Exclusivity for Haemophilia Products HOW TO CONSIDER THE NEW EXTENDED HALF LIFE FACTORS Jerry S. Powell, MD Professor of Hematology and Oncology,
Add to Reading List

Document Date: 2013-10-29 14:15:58

Open Document

File Size: 432,75 KB

Share Result on Facebook

Company

Morningstar / /

Country

United States / /

Currency

USD / /

Facility

Thrombosis Center of University of California at Davis CALIFORNIA / /

IndustryTerm

life products / venous access devices / pharmaceutical / treatment of hemophilia / /

MedicalCondition

genetic disease / Intracranial hemorrhage / rare disease / hemophilia / /

Organization

FDA / University of California / World Federation of Hemophilia / Hemostasis and Thrombosis Center / /

Person

Oncology / /

Position

Analyst / Professor of Hematology / Director / /

ProvinceOrState

California / /

SocialTag